BRISTOL, Tenn. (AP) ¿ King Pharmaceuticals Inc. said Monday that it launched pain drug Embeda, which is designed to be abuse-resistant. King said it began shipping the extended-release capsules in six dosages ranging from 20 milligrams to 100 milligrams. Embeda contains morphine and a core of a second drug called naltrexone. If the drug is crushed or chewed, the naltrexone is released and the high from the morphine is canceled out. Pain pills are often abused by users who grind them up to snort or inject. The Food and Drug Administration approved Embeda for moderate to severe chronic pain in August. King is also developing another abuse-resistant painkiller, Remoxy, with partner Pain Therapeutics Inc. King asked the FDA to approve Remoxy in December, but the agency requested more data. King plans to resubmit its application in the middle of 2010. In afternoon trading, King shares added 14 cents to $10.95.
More from Food & Drink
Red Robin Stock Higher as Burger Chain Swings to Second-Quarter Profit
The burger chain reiterated its full-year outlook.
Divorce, Single Women and Retail: a Marriage Made For Your Portfolio
Morgan Stanley did some serious research on this. Stick with us here.
Exclusive: CBD-Infused Happy Tea to IPO in January
Happy Tea founder Michael Gonzalez sat down with TheStreet to talk about his company's next steps.
Hain Celestial Drops After J.P. Morgan Turns Bearish
J.P. Morgan lowers its rating on the stock of the manufactured food company to underweight from neutral.